Spots Global Cancer Trial Database for melanoma stage iv
Every month we try and update this database with for melanoma stage iv cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma | NCT03153085 | Melanoma Stage ... Melanoma Stage ... | TBI-1401(HF10) Ipilimumab | 20 Years - | Takara Bio Inc. | |
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | NCT04598009 | Melanoma Stage ... Melanoma Stage ... | Binimetinib Imatinib | 18 Years - | University of California, San Francisco | |
| Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | NCT05652673 | Melanoma Stage ... Melanoma Stage ... Immunotherapy Toxicity, Drug | nivolumab | 18 Years - | Erasmus Medical Center | |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | NCT05848739 | Breast Cancer M... Pancreatic Canc... NSCLC, Metastat... Synovial Sarcom... Colon Cancer Metastatic Colo... Melanoma Recurr... Metastatic Skin... Melanoma Stage ... Triple Negative... TNBC - Triple-N... Cholangiocarcin... Ovarian Cancer Metastatic Mela... Hepatocellular ... | ST316 | 18 Years - | Sapience Therapeutics | |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | NCT06319196 | Cutaneous Melan... Melanoma Stage ... Mucosal Melanom... | Opdualag Nivolumab | 18 Years - | University Health Network, Toronto | |
| SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study) | NCT04079166 | Malignant Melan... Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... | SCIB1 DNA vacci... | 18 Years - | Scancell Ltd | |
| IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | NCT04562129 | Melanoma Stage ... Melanoma Stage ... Inoperable Dise... | Interleukin-2 Ipilimumab Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain | NCT03605771 | Melanoma Stage ... Melanoma Stage ... Advanced Cancer | Daily Clinical ... | 18 Years - | Grupo Español Multidisciplinar de Melanoma | |
| Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) | NCT03340129 | Melanoma Stage ... | Ipilimumab Nivolumab Stereotactic Ra... Salvage therapy | 18 Years - 120 Years | Melanoma Institute Australia | |
| High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma | NCT03991130 | Melanoma Stage ... Renal Cell Carc... | IL-2 and Nivolu... | 18 Years - | University of California, San Diego | |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | NCT04478279 | Glioblastoma Melanoma Stage ... Breast Cancer Prostate Cancer Glioblastoma Mu... GBM Brain Cancer Metastatic Brea... Metastatic Mela... Metastatic Pros... Melanoma Recurr... Prostate Cancer... Recurrent Gliob... Newly Diagnosed... | ST101 Temozolomide Radiation | 18 Years - | Sapience Therapeutics | |
| A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | NCT04521075 | Melanoma Stage ... Unresectable Me... NSCLC Stage IV | Fecal Microbial... | 18 Years - | Ella Therapeutics Ltd | |
| IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | NCT04562129 | Melanoma Stage ... Melanoma Stage ... Inoperable Dise... | Interleukin-2 Ipilimumab Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy | NCT03353402 | Melanoma Stage ... Unresectable St... | Fecal Microbiot... | 18 Years - | Sheba Medical Center | |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma | NCT05732805 | Melanoma Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... Melanoma Unrese... Melanoma Metast... Melanoma Advanc... | BCD-217 BCD-100 Placebo | 18 Years - | Biocad | |
| High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma | NCT03991130 | Melanoma Stage ... Renal Cell Carc... | IL-2 and Nivolu... | 18 Years - | University of California, San Diego | |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | NCT05970497 | Cancer Melanoma Stage ... Melanoma Stage ... Cutaneous Melan... Osteosarcoma Carcinoma, Squa... Carcinoma, Basa... | KB707 | 18 Years - | Krystal Biotech, Inc. | |
| Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma | NCT04513028 | Melanoma Stage ... Melanoma Stage ... | Beta-Glucan | 18 Years - | University of Louisville | |
| Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment | NCT04045691 | Melanoma Stage ... Melanoma Stage ... | Encorafenib Binimetinib | 18 Years - | Pierre Fabre Pharma GmbH | |
| A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | NCT04521075 | Melanoma Stage ... Unresectable Me... NSCLC Stage IV | Fecal Microbial... | 18 Years - | Ella Therapeutics Ltd | |
| Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis | NCT05068453 | Melanoma Stage ... | Recombinant Onc... Recombinant hum... RT | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| FMT to Convert Response to Immunotherapy | NCT05251389 | Melanoma Stage ... Melanoma Stage ... | Fecal microbiot... | 18 Years - | The Netherlands Cancer Institute | |
| Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) | NCT03340129 | Melanoma Stage ... | Ipilimumab Nivolumab Stereotactic Ra... Salvage therapy | 18 Years - 120 Years | Melanoma Institute Australia | |
| Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors | NCT04990726 | Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Melanoma, Stage... Melanoma Stage ... | Assessment Biospecimen Col... Quality-of-Life... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma | NCT06204991 | Melanoma Stage ... Melanoma Stage ... Melanoma | ADP-TILIL7 Cyclophosphamid... Fludarabine Pho... Proleukin | 18 Years - 75 Years | Herlev Hospital | |
| Surgery of Melanoma Metastases After Systemic Therapy | NCT04242329 | Melanoma Melanoma Stage ... Metastatic Mela... Surgery | Surgical metast... Immunotherapy | 18 Years - | Vastra Gotaland Region | |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | NCT05848739 | Breast Cancer M... Pancreatic Canc... NSCLC, Metastat... Synovial Sarcom... Colon Cancer Metastatic Colo... Melanoma Recurr... Metastatic Skin... Melanoma Stage ... Triple Negative... TNBC - Triple-N... Cholangiocarcin... Ovarian Cancer Metastatic Mela... Hepatocellular ... | ST316 | 18 Years - | Sapience Therapeutics | |
| A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma | NCT05370807 | Melanoma Stage ... Melanoma Stage ... | Regorafenib 40 ... Triplet therapy | 18 Years - | Universitair Ziekenhuis Brussel | |
| Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis | NCT05070221 | Melanoma Stage ... | Recombinant Onc... Recombinant hum... Axitinib | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells | NCT04628806 | Melanoma Stage ... Sarcoma Squamous Cell C... Pancreatic Canc... Prostate Cancer Breast Cancer S... | CTC isolation b... | 18 Years - | Charite University, Berlin, Germany | |
| Appropriate Dosing to Optimise Personalised Cancer Treatments | NCT04154163 | Melanoma Stage ... Melanoma Stage ... Ovarian Cancer Renal Cancer St... Renal Cancer St... Lung Cancer, No... | Dried blood Spo... Venous blood sa... | 18 Years - 100 Years | University of Dundee | |
| Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study | NCT03879395 | Melanoma Stage ... Melanoma Metast... Abdominal Tumor | Abdominal surge... | 18 Years - | Vastra Gotaland Region | |
| SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | NCT03161431 | Melanoma Stage ... Melanoma Stage ... | SX-682 Pembrolizumab | 18 Years - | Syntrix Biosystems, Inc. | |
| Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease | NCT04330430 | Melanoma Stage ... Melanoma Stage ... | T-VEC | 18 Years - | The Netherlands Cancer Institute | |
| Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study | NCT03879395 | Melanoma Stage ... Melanoma Metast... Abdominal Tumor | Abdominal surge... | 18 Years - | Vastra Gotaland Region | |
| Versatile Ampification Single-Molecule Detection in Liquid Biopsy | NCT05940311 | Liquid Biopsy Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... BRAF V600E | Affinity Mediat... | 18 Years - | Regina Elena Cancer Institute | |
| Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | NCT04455503 | Melanoma Stage ... Melanoma Stage ... | EVX-02A EVX-02B EVX-02A OR EVX-... | 18 Years - | Evaxion Biotech A/S | |
| Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | NCT03161756 | Melanoma Stage ... Melanoma Stage ... Melanoma | Denosumab Nivolumab Ipilimumab | 18 Years - | Melanoma and Skin Cancer Trials Limited | |
| Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma | NCT04139902 | Melanoma Stage ... Melanoma Stage ... | Dostarlimab (TS... Dostarlimab (TS... | 18 Years - | University of Pittsburgh | |
| Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment | NCT04045691 | Melanoma Stage ... Melanoma Stage ... | Encorafenib Binimetinib | 18 Years - | Pierre Fabre Pharma GmbH | |
| Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells | NCT04628806 | Melanoma Stage ... Sarcoma Squamous Cell C... Pancreatic Canc... Prostate Cancer Breast Cancer S... | CTC isolation b... | 18 Years - | Charite University, Berlin, Germany | |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | NCT06319196 | Cutaneous Melan... Melanoma Stage ... Mucosal Melanom... | Opdualag Nivolumab | 18 Years - | University Health Network, Toronto | |
| Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | NCT05296564 | Sarcoma, Synovi... Sarcoma,Soft Ti... Melanoma Stage ... Triple Negative... Metastatic Canc... Non Small Cell ... Bladder Urothel... Neuroblastoma, ... Ovary Cancer | CYCLOPHOSPHAMID... Cyclophosphamid... HBI 0201-ESO TC... Aldesleukin | 18 Years - 70 Years | Hadassah Medical Organization | |
| FMT to Convert Response to Immunotherapy | NCT05251389 | Melanoma Stage ... Melanoma Stage ... | Fecal microbiot... | 18 Years - | The Netherlands Cancer Institute | |
| Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) | NCT03340129 | Melanoma Stage ... | Ipilimumab Nivolumab Stereotactic Ra... Salvage therapy | 18 Years - 120 Years | Melanoma Institute Australia | |
| Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy | NCT04904120 | Melanoma (Skin) Melanoma Stage ... Melanoma, Uveal Melanoma, Mucos... | [203Pb]VMT01 [68Ga]VMT02 | 18 Years - 89 Years | Perspective Therapeutics | |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | NCT04410445 | Melanoma Melanoma Stage ... Melanoma Stage ... Melanoma (Skin) | Bempegaldesleuk... Nivolumab | 12 Years - | Nektar Therapeutics | |
| Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma | NCT04526899 | Melanoma Stage ... Melanoma Stage ... Unresectable Me... | BNT111 Cemiplimab | 18 Years - | BioNTech SE | |
| Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma | NCT05303493 | NSCLC Stage IV Melanoma Stage ... Unresectable Me... Advanced Non-Sm... | Camu Camu Capsu... | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders | NCT05286294 | Melanoma Stage ... Head and Neck S... Cutaneous Squam... MSI-High Clear Cell Rena... Non-small Cell ... | Fecal Microbiot... | 18 Years - | Oslo University Hospital | |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma | NCT05732805 | Melanoma Melanoma (Skin) Melanoma Stage ... Melanoma Stage ... Melanoma Unrese... Melanoma Metast... Melanoma Advanc... | BCD-217 BCD-100 Placebo | 18 Years - | Biocad | |
| A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma | NCT04007588 | Melanoma Stage ... Melanoma Stage ... | Nivolumab BMS-986205 Ipilimumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | NCT04521075 | Melanoma Stage ... Unresectable Me... NSCLC Stage IV | Fecal Microbial... | 18 Years - | Ella Therapeutics Ltd | |
| Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | NCT06295159 | Melanoma Stage ... Melanoma Stage ... Advanced Melano... Melanoma | Nivolumab Nivolumab + Rel... Ipilimumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Intrathecal Double Checkpoint Inhibition | NCT05598853 | Leptomeningeal ... Non-small Cell ... Melanoma Stage ... | intrathecal niv... | 18 Years - 100 Years | University of Zurich | |
| Dabrafenib and/or Trametinib Rollover Study | NCT03340506 | Melanoma Non Small Cell ... Solid Tumor Rare Cancers High Grade Glio... | dabrafenib trametinib | 18 Years - 100 Years | Novartis | |
| Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | NCT04455503 | Melanoma Stage ... Melanoma Stage ... | EVX-02A EVX-02B EVX-02A OR EVX-... | 18 Years - | Evaxion Biotech A/S | |
| Surgery of Melanoma Metastases After Systemic Therapy | NCT04242329 | Melanoma Melanoma Stage ... Metastatic Mela... Surgery | Surgical metast... Immunotherapy | 18 Years - | Vastra Gotaland Region | |
| IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | NCT04562129 | Melanoma Stage ... Melanoma Stage ... Inoperable Dise... | Interleukin-2 Ipilimumab Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE | NCT05171374 | Melanoma Stage ... Melanoma Stage ... Melanoma | Dabrafenib Trametinib | 18 Years - | MelanomaPRO, Russia | |
| Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | NCT04741997 | Melanoma Stage ... Melanoma Stage ... BRAF V600 Mutat... | Encorafenib Pil... Binimetinib Pil... Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis | NCT04305145 | Melanoma Stage ... Melanoma Stage ... Skin Cancer Sta... Skin Cancer Sta... Drug-Induced Co... Drug Toxicity Immune-related ... | Infliximab Methylprednisol... Prednisone | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
